Hendrik Fuchs

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 20

Top Venues

PharmacoEconomics - open

Toxins

ACS applied materials & interfaces

Journal of immunology research

Charité Universitätsmedizin Berlin Campus Virchow-Klinikum

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Charité Universitätsmedizin Berlin Campus Virchow-Klinikum Nov 01 1997

Germany

Laboratory Head, Research Director, Deputy Institute's Director :: Institut für Laboratoriumsmedizin, Klinische Chemie und Pathobiochemie

Publications

Niklaus Meier, Hendrik Fuchs, Katya Galactionova, Cedric Hermans, Mark Pletscher, Matthias E Schwenkglenks
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany. PharmacoEconomics - open 8 (3) (2024)
Niklaus Meier, Hendrik Fuchs, Katya Galactionova, Cedric Hermans, Mark Pletscher, Matthias E Schwenkglenks
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany. PharmacoEconomics - open 8 (3) (2024)
Meike Kolster, Alexander Sonntag, Christoph Weise, Juan Correa, Hendrik Fuchs, Wolfgang Walther, Eduardo Fernandez-Megia, Alexander Weng
Broadening the Scope of Sapofection: Cationic Peptide-Saponin Conjugates Improve Gene Delivery In Vitro and In Vivo . ACS applied materials & interfaces 16 (28) (2024)
Niklaus Meier, Hendrik Fuchs, Katya Galactionova, Cedric Hermans, Mark Pletscher, Matthias E Schwenkglenks
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany. PharmacoEconomics - open (2024)
Niklaus Meier, Hendrik Fuchs, Katya Galactionova, Cedric Hermans, Mark Pletscher, Matthias E Schwenkglenks
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany. PharmacoEconomics - open 8 (3) (2024)
Niklaus Meier, Hendrik Fuchs, Katya Galactionova, Cedric Hermans, Mark Pletscher, Matthias E Schwenkglenks
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany. PharmacoEconomics - open 8 (3) (2024)
Niklaus Meier, Hendrik Fuchs, Katya Galactionova, Cedric Hermans, Mark Pletscher, Matthias E Schwenkglenks
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany. PharmacoEconomics - open 8 (3) (2024)
Niklaus Meier, Hendrik Fuchs, Katya Galactionova, Cedric Hermans, Mark Pletscher, Matthias E Schwenkglenks
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany. PharmacoEconomics - open 8 (3) (2024)
Meike Kolster, Alexander Sonntag, Christoph Weise, Juan Correa, Hendrik Fuchs, Wolfgang Walther, Eduardo Fernandez-Megia, Alexander Weng
Broadening the Scope of Sapofection: Cationic Peptide-Saponin Conjugates Improve Gene Delivery In Vitro and In Vivo . ACS applied materials & interfaces 16 (28) (2024)
Meike Kolster, Alexander Sonntag, Christoph Weise, Juan Correa, Hendrik Fuchs, Wolfgang Walther, Eduardo Fernandez-Megia, Alexander Weng
Broadening the Scope of Sapofection: Cationic Peptide-Saponin Conjugates Improve Gene Delivery In Vitro and In Vivo . ACS applied materials & interfaces 16 (28) (2024)
Niklaus Meier, Hendrik Fuchs, Katya Galactionova, Cedric Hermans, Mark Pletscher, Matthias E Schwenkglenks
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany. PharmacoEconomics - open 8 (3) (2024)
Meike Kolster, Alexander Sonntag, Christoph Weise, Juan Correa, Hendrik Fuchs, Wolfgang Walther, Eduardo Fernandez-Megia, Alexander Weng
Broadening the Scope of Sapofection: Cationic Peptide-Saponin Conjugates Improve Gene Delivery In Vitro and In Vivo . ACS applied materials & interfaces (2024)
Paulina Koczurkiewicz, Karolina Grabowska, Elżbieta Karnas, Kamil Piska, Dawid Wnuk, Katarzyna Klas, Agnieszka Galanty, Katarzyna Wójcik-Pszczoła, Marta Michalik, Elżbieta Pękala, Hendrik Fuchs, Irma Podolak
Saponin Fraction CIL1 from Lysimachia ciliata L. Enhances the Effect of a Targeted Toxin on Cancer Cells. Pharmaceutics 15 (5) (2023)
Hossein Panjideh, Nicole Niesler, Alexander Weng, Hendrik Fuchs
Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861. Toxins 14 (7) (2022)
Hossein Panjideh, Nicole Niesler, Alexander Weng, Hendrik Fuchs
Correction: Panjideh et al. Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861. Toxins 2022, 14 , 478. Toxins 14 (10) (2022)
Anne-Catherine Lehnen, Alain M Bapolisi, Melanie Krass, Ahmad AlSawaf, Jan Kurki, Sebastian Kersting, Hendrik Fuchs, Matthias Hartlieb
Shape Matters: Highly Selective Antimicrobial Bottle Brush Copolymers via a One-Pot RAFT Polymerization Approach. Biomacromolecules (2022)
Xiangli Zhao, Wenhan Wang, Kai Zhang, Jingya Yang, Hendrik Fuchs, Hua Fan
Involvement of CD26 in Differentiation and Functions of Th1 and Th17 Subpopulations of T Lymphocytes. Journal of immunology research 2021 (2021)
Ajmal Zarinwall, Mazdak Asadian-Birjand, Didem Ag Seleci, Viktor Maurer, Alexandra Trautner, Georg Garnweitner, Hendrik Fuchs
Magnetic Nanoparticle-Based Dianthin Targeting for Controlled Drug Release Using the Endosomal Escape Enhancer SO1861. Nanomaterials (Basel, Switzerland) 11 (4) (2021)
Alexandra Fischer, Isis Wolf, Hendrik Fuchs, Anie Priscilla Masilamani, Philipp Wolf
Pseudomonas Exotoxin A Based Toxins Targeting Epidermal Growth Factor Receptor for the Treatment of Prostate Cancer. Toxins 12 (12) (2020)
Hendrik Fuchs
Dianthin and Its Potential in Targeted Tumor Therapies. Toxins 11 (10) (2019)

Hendrik Fuchs.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hendrik Fuchs